ArticleTranslational lung cancer research2025
Radiotherapy
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial lung disease (ILD) and lung cancer are often associated, and ILD-associated lung cancer is a difficult condition to treat. Radiotherapy (RTx) is one of a standard therapeutic modalities for lung cancer, but pre-existing ILD is known to be a significant risk factor for developing severe radiation pneumonitis (RP) after treatment. In this context, there is a demand for alternative treatment modalities for ILD-associated localized lung cancer. Photodynamic therapy (PDT) is a minimally invasive treatment modality for lung cancer that can be performed endoscopically. In this study, we investigated proof-of-concept animal studies comparing RTx Methods: For the mouse tumor study, NCr-Foxn1nu athymic mice were subcutaneously inoculated with A549 or H460 human lung cancer cells to unilateral thigh and followed for growth until 8-12 mm sized. Ultrasmall nanostructured nanoparticle porphylipoprotein (PLP) was used in this study. The mice were divided into three intervention groups; control, RTx, and PDT. RTx group received a single 20 Gy local irradiation, while PDT group received an intravenous PLP (4 mg/kg) 24 hours before treatment, followed by laser ablation (671 nm) at 100 J/cm Results: In the mouse xenograft model, PLP biodistribution showed the best tumor-to-contralateral background muscle ratio at 24 hours post-injection. In day 7, both RTx and PDT showed a significant tumor volume difference in A549 and H460 xenografts over control, while PDT showed a significant tumor volume difference in A549 xenograft compared to RTx. In rat ILD model, chest CT showed that BLM + RTx exhibited increased lung infiltrates at week 15 compared to BLM + PDT. Leukocyte cell fractionation of bronchoalveolar lavage at 15 weeks showed that BLM + RTx had significantly higher cell counts than BLM + PDT or control in total leukocyte, neutrophil, and macrophage. In Ashcroft's lung fibrosis pathology score, BLM + RTx showed more significant score increases over control, BLM, or BLM + PDT. Conclusions: Despite the differences in dose delivery between RTx and PDT, PDT demonstrated comparable antitumor efficacy to RTx in mouse xenograft model and a safer pulmonary toxicity profile than RTx in rat ILD model. PDT is possibly a promising treatment modality for lung cancer associated with ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.